IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital, networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in approximately 80 early-stage to mature businesses across three main sectors -- Life Sciences, Technology, and Cleantech. The Company is listed on the Main Market of the London Stock Exchange under the code IPO.
News
3.24K
Portfolio
10
Mentions
285
Location: United Kingdom, England, London
Employees: 51-200
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 10
| Date | Name | Website | Total Raised | Location |
| 13.05.2026 | Mantle8 | mantle8.com | $42.25M | France |
| 16.04.2026 | Storm Ther... | stormtherapeutics.com | $145.62M | United Kin... |
| 17.11.2025 | Artios | artiospharma.com | $354.78M | United Kin... |
| 15.11.2025 | RAGE Biote... | ragebiotech.com | $18.93M | Australia |
| 15.10.2025 | Mission Th... | missiontherapeutics.com | $191.92M | United Kin... |
| 01.10.2025 | OXCCU | oxccu.com | $53.04M | United Kin... |
| 24.07.2023 | Crescendo ... | crescendobiologics.com | $133.79M | United Kin... |
| 21.09.2020 | AccelerCom... | accelercomm.com | $49.79M | United Kin... |
| 04.02.2019 | C-Capture ... | c-capture.co.uk | $15.88M | United Kin... |
| 17.02.2012 | TheySay | theysayanalytics.com | $791.44K | United Kin... |
News 3243
| Date | Title | Description |
| 21.02.2023 | AMSL Aero - 'Vertiia' all-electric aircraft takes maiden flight in historic first for Australian aviation | Australian green aerospace company AMSL Aero today announced that Vertiia , t he world’s most efficient and longest-range Electric Vertical Take Off and Landing ( eVTOL ) aircraft , has successfully completed its maiden test fl... |
| 21.02.2023 | Quantum Motion Technologies Ltd - Raises £42m investment round led by Bosch Ventures | Largest funding round in UK Quantum Computing Quantum Motion, a UK-based quantum computing scale-up founded by Professor John Morton, UCL, and Professor Simon Benjamin, Oxford University, has raised over £42 million in equity fundi... |
| 15.02.2023 | Audioscenic - Kicks Off 2023 With Series a Round Investment and Industry Recognition at CES | Innovative spatial audio brand Audioscenic looks to the future with increased resources and ambitious design roadmap SOUTHAMPTON, UNITED KINGDOM, 15th February 2023 – Audioscenic , developers of innovative 3D audio beamforming tec... |
| 03.02.2023 | Itaconix plc - Placing, Subscription and Open Offer and Notice of General Meeting | Placing, Subscription and Open Offer and Notice of General Meeting The Board of Itaconix plc, a leading innovator in sustainable plant-based polymers used to decarbonise everyday consumer products, is pleased to announce th... |
| 27.01.2023 | Hysata - Australia and Germany strengthen hydrogen partnership | Today, Minister for Climate Change and Energy Chris Bowen met with German Minister for Education and Research Bettina Stark-Watzinger in Berlin to announce four new joint projects under the German-Australia Hydrogen Innovation and Technol... |
| 25.01.2023 | First Light Fusion Ltd - To build gain demonstration facility at UKAEA’s Culham Campus | UKAEA and First Light Fusion to construct a new facility to house First Light’s new net energy gain demonstrator (“Machine 4”) in Oxford, UK The agreement will see both parties developing the building at Culham Campus Architec... |
| 17.01.2023 | Oxford Nanopore Technologies plc - Trading update | Total Group revenue for fiscal year 2022 is expected to be approximately £199 million Core Life Science Research Tools revenue is expected to be approximately £147 million during the period Life Science Research Tools revenue is e... |
| 16.01.2023 | Intelligent Ultrasound Group plc - Trading Update | Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation , continued to make significant progress across the business and announces t... |
| 11.01.2023 | Oxbotica Ltd - Raises US$140m Series C investment to deploy its operating system for universal autonomy™ around the world | ● Oxbotica, a global leader in autonomous vehicle software, raises US$140 million in Series C investment round ● Financial and strategic investors from across the globe include Aioi Nissay Dowa Insurance Co., Ltd, bp ventures, Tencent, a... |
| 11.01.2023 | Hinge Health launches physical therapy house calls | In-home physical therapy complements Hinge Health's digital musculoskeletal care, delivering on the vision of creating a health care system built around each person’s needs SAN FRANCISCO, Jan. 10, 2023 – Today, Hinge Health , the mus... |
| 05.01.2023 | Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics | $30 million convertible note financing co-led by ARCH Venture Partners, Parker Institute for Cancer Immunotherapy, and Westlake Village BioPartners expands investor base to include leading US life science venture capital firms Clinic... |
| 14.12.2022 | STORM Therapeutics Ltd - STORM Therapeutics announces closing of USD $30M Series B financing | STORM Therapeutics announces closing of USD $30M Series B financing Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias Financing will further expand... |
| 13.12.2022 | First Light Fusion Ltd - FLF congratulates NIF on its maiden gain result | First Light Fusion congratulates NIF on its maiden gain result National Ignition Facility, Lawrence Livermore National Laboratory, has confirmed it has achieved “gain”, more energy out than in, for the first time Gain from inertia... |
| 06.12.2022 | Pulmocide Ltd - Pulmocide Raises $52 Million to Fund Additional Late-Stage Development of Opelconazole | Strong support from high-quality new and existing investors provides capital for opelconazole development and pre-commercialization activities well beyond ongoing registration studies LONDON, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pulmocide... |
| 05.12.2022 | Istesso Ltd - Announces FDA Fast Track and Orphan Drug designation for MBS2320 | Istesso Limited, the immunometabolism drug discovery and development company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Istesso’s investigational metabolic reprogramming agent,... |
| 29.11.2022 | Microbiotica Ltd - Microbiotica announces transition of leadership | Co-founder and CEO Mike Romanos steps down after six years to take up role of Associate Dean of Enterprise in the Faculty of Medicine at Imperial College Tim Sharpington, Microbiotica COO and experienced industry executive, appointed... |
| 28.11.2022 | First Light Fusion Ltd - Targets 60 MW pilot plant to accelerate tritium production | First Light Fusion targets 60 MW pilot plant to accelerate tritium production 60 MW pilot fusion power plant, c. $570 million capex, set to produce 2 kg of excess tritium per year Pilot plant designed to prove the integrated engin... |
| 22.11.2022 | Diffblue Ltd - Expands AI for Code Platform – Raises $8m in New Funding | UK pioneer in using artificial intelligence (AI) to write software extends platform to increase speed, confidence and insight during development; AlbionVC leads funding round to target $40 billion market opportunity OXFORD, United ... |
| 11.11.2022 | Intelligent Ultrasound Group plc - Placing and Subscription to raise £5.2 million and Notice of General Meeting | Intelligent Ultrasound Group plc (“Intelligent Ultrasound” or the “Company” or the “Group”) Placing and Subscription to raise £5.2 million and Notice of General Meeting Intelligent Ultrasound (AIM: IUG), the ultraso... |
| 20.10.2022 | Intelligent Ultrasound Group plc - FDA grants ScanNav Anatomy PNB clearance for sale in the USA | Intelligent Ultrasound Group plc (the “Group” or the “Company” or “Intelligent Ultrasound”) FDA grants ScanNav Anatomy PNB clearance for sale in the USA Intelligent Ultrasound (AIM: IUG), the 'classroom to clinic' ultraso... |
| 11.10.2022 | Genomics plc - Announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches | Genomics plc announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approaches Genomics plc is the world-leader in the analysis and use of genetic data to understand people’s r... |
| 14.09.2022 | Itaconix plc - Half year results for the period ended 30 June 2022 | Itaconix plc ("Itaconix" or the "Company") Half year results for the period ended 30 June 2022 Itaconix (LSE: ITX) (OTCQB: ITXXF), a leading innovator in sustainable plant-based polymers used... |
| 13.09.2022 | Oxford Nanopore Technologies plc - Interim results for the period ended 30 June 2022 | Oxford Nanopore Technologies plc Interim results for the six months ended 30 June 2022 Strong growth in core LSRT business; re-affirming full year guidance Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" ... |
| 31.08.2022 | Istesso Ltd - Announces initiation of Phase 2b trial of MBS2320 | MBS2320 administered to participants with moderate-to-severe Rheumatoid Arthritis Istesso Limited, the immunometabolism drug discovery and development company, today announces the initiation of IST-06. This is a phase 2b randomized, mu... |
| 30.08.2022 | Diurnal Group plc - Recommended cash acquisition by Neurocrine Biosciences, Inc. | For the full announcement, please click here . NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICT... |
| 26.07.2022 | Diurnal Group plc - Trading Update | Revenues in line with current expectations; strong sales growth (+104%) driven by good Alkindi ® performance and initial sales of Efmody ® Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in... |
| 22.07.2022 | First Light Fusion - Strikes Long-Term Collaboration Agreement with Engineering Leaders IDOM | Long term collaboration agreement to develop the reactor chamber for a commercial projectile fusion power plant OXFORD, England, July 21, 2022 - First Light Fusion, the Oxford-based fusion energy pioneer, has entered a long-term collab... |
| 21.07.2022 | Intelligent Ultrasound Group plc - Trading update | Intelligent Ultrasound Group plc (the "Group") Trading update Impressive growth in H1 2022 Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intellige... |
| 19.07.2022 | Econic Technologies Ltd – Announces partnership with Manali Petrochemicals | The agreement with Manali Petrochemicals Limited will see the Indian market leader retrofit an existing production facility to commercialise Econic’s carbon-to-value technology London, 19 July 2022 – Econic Technologies, the UK’s deep... |
| 11.07.2022 | Oxford Nanopore Technologies plc - Sale and leaseback of headquarters building to The Oxford Science Park | Oxford Nanopore Technologies plc ("Oxford Nanopore") Sale and leaseback of headquarters building to The Oxford Science Park Oxford Nanopore Technologies plc (LSE: ONT), the company behind a new generation of molecular... |
| 30.06.2022 | Oxford Nanopore Technologies plc - Duncan Tatton-Brown appointed as Non-Executive Chair | Oxford Nanopore Technologies plc ("Oxford Nanopore" or the "Group") Duncan Tatton-Brown appointed as Non-Executive Chair Oxford Nanopore Technologies plc, the company behind a new generation of molecular sensi... |
| 23.06.2022 | Mirriad Advertising plc - Board changes | Mirriad, the leading in-content advertising company, announces the appointments of Nicole McCormack and Lois Day to the board of the Company as Non-Executive Directors, with immediate effect. The appointments align with the Company's e... |
| 22.06.2022 | Intelligent Ultrasound Group plc - AGM Statement | Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces that at the AGM due to be held today at 11:00am at the offices of M... |
| 01.06.2022 | Diurnal Group plc - First patient dosed in pivotal Phase 3 trial | First patient dosed in pivotal Phase 3 CONnECT clinical trial for US and Japanese markets Headline data from CONnECT is anticipated in 2024 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs i... |
| 30.05.2022 | Mirriad Advertising plc - Mirriad announces programmatic collaboration with Magnite | Mirriad announces programmatic collaboration with Magnite New integration will bring scale and automation to the in-content advertising format Mirriad, the leading in-content advertising company, today announces its collaboration wi... |
| 23.05.2022 | Deepmatter Group plc - Alan Aubrey appointed Chairman of DeepMatter | DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the digital chemistry data and software company, announces the appointment of Alan Aubrey as non-executive Chairman after the AGM on the 27 May 2022. He take... |
| 20.05.2022 | Oxford Nanopore Technologies plc - Announces tech updates | Oxford Nanopore delivers technology update at annual London Calling conference: bringing together years of innovation to showcase one sensing platform for all biological analyses Summary: At the annual London Calling conference, C... |
| 13.05.2022 | Oxford Nanopore Technologies plc - Chosen for comprehensive human genome programme | Oxford Nanopore sequencing selected to generate comprehensive insights by characterising a more complete genome using samples from the 1000 Genomes Project Oxford Nanopore technology will enable the 1000 Genomes Project, spearheaded ... |
| 03.05.2022 | Applied Graphene plc - New data package for chemical resistant coatings | AGM launches new application package for chemical resistant graphene enhanced coatings AGM Graphene Nanoplatelets Outperform Traditional Protective Additives in Latest Testing Applied Graphene Materials (LSE:AGM), the producer of ... |
| 25.04.2022 | Diurnal Group plc - Distribution agreement signed with EffRx | Diurnal Group plc Efmody® distribution and marketing agreement signed with EffRx for Switzerland Extends Company's existing agreement with EffRx for Alkindi® in Switzerland EffRx to submit Market Authorisation Application for Efm... |
| 20.04.2022 | Itaconix plc - Trading update | Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based specialty polymers used as essential ingredients in everyday consumer products, is pleased to update the market on current trading. The Company reports that trading... |
| 20.04.2022 | DIurnal Group plc - Distribution agreement signed with Er-Kim for Greece, Cyprus and Malta targeting a market opportunity of approximately €7m | Deepens existing distribution relationship with Er-Kim covering Alkindi ® and Efmody ® In line with Company's strategy to commercialise products outside of key markets; Alkindi ® and Efmody ® now being commercialised in 20 cou... |
| 11.04.2022 | GripAble Ltd - Raises $11m in Series A funding to deliver data-driven neuro and musculoskeletal rehab | GripAble , a London-based digital healthcare start-up delivering rehabilitation programmes to people with neurological and musculoskeletal conditions, today announced the successful close of an $11m Series A funding round. The new fun... |
| 07.04.2022 | Kynos Therapeutics Ltd - Emerges from stealth with £9m financing and Phase 1-ready KMO Inhibitor | Spin-out from the University of Edinburgh commercialising a decade of drug discovery research on kynurenine 3-monooxygenase (KMO), a pivotal enzyme in the kynurenine pathway of tryptophan metabolism Kynos programmes are focused on ... |
| 06.04.2022 | Applied Graphene Materials plc - Interim results for the six months ended 31 January 2022 | Interim results for the six months ended 31 January 2022 Applied Graphene Materials, the producer of specialty graphene materials, is pleased to announce its interim results for the six months ended 31 January 2022. Highlights ... |
| 05.04.2022 | First Light Fusion Ltd - Achieves world first fusion result, proving unique new target technology | First Light achieves world first fusion result, proving unique new target technology Fusion shown with projectile approach for first time, validated by UKAEA Breakthrough achieved faster and cheaper than traditional fusion approac... |
| 04.04.2022 | Diurnal Group plc - Directorate Change and Management Updates | Directorate Change and Management Updates Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that following 14 years with the Company, Martin W... |
| 04.04.2022 | Oxford Nanopore Technologies plc - Genomics England expands use of Oxford Nanopore sequencing in cancer | Genomics England expands use of Oxford Nanopore sequencing in cancer Oxford Nanopore technology will be used by Genomics England to investigate and validate at increasing scale the benefits of sequencing for improving patient care and ... |
| 01.04.2022 | Oxford Nanopore Technologies plc - Entry into settlement agreement with Department of Health and Social Care | The Department of Health and Social Care (DHSC) and Oxford Nanopore Technologies plc (ONT) reached an amicable resolution of the dispute relating to the contract dated 30 July 2020 for the supply of certain LamPORE™ devices and testing kits... |
| 31.03.2022 | Mirriad Advertising Plc - In-content advertising increases reach | Mirriad Advertising plc In-content advertising dramatically increases reach Mirriad whitepaper illustrates the effectiveness of the format, spurring improved audience engagement and business growth for brands Mirriad, the leading... |
| 30.03.2022 | Diurnal Group plc- Distribution agreement signed with Vector Pharma for Alkindi ® | Distribution agreement signed with Vector Pharma for Alkindi ® Exclusive partnership covers 14 countries across the Middle East and North Africa Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient ... |
| 30.03.2022 | Oxford Nanopore Technologies plc - Shows new high-accuracy, high-output chemistry | Oxford Nanopore technology update: CTO Clive G Brown unveils latest sequencing chemistry with highest performance to date, Short Fragment Mode and latest methylation performance evaluations 30 th March 2022 Clive G Brown, CTO, Oxfor... |
| 29.03.2022 | Abingdon Health plc - Strategic collaboration with Vatic Health Limited | Focused on the development, manufacturing and commercialisation of infectious disease lateral flow self-tests Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests... |
| 29.03.2022 | Abingdon Health plc - Interim Results for the six months ended 31 December 2021 | Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces its unaudited interim results for the six months ended 31 December 2021. Operational Highlights (i... |
| 29.03.2022 | Abingdon Health plc - Strategic collaboration with DeepVerge plc | Focused on the development, manufacturing and commercialisation of lateral flow tests to support DeepVerge's Modern Water and Life Science divisions Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer... |
| 22.03.2022 | Oxford Nanopore Technologies plc - Preliminary results for the year ended 31 December 2021 | A year of exceptional technical, commercial and financial progress; increase in 2022 and 2023 revenue guidance Oxford Nanopore Technologies plc (the "Group"), the company behind a new generation of nanopore-based sensing tech... |
| 22.03.2022 | Diurnal Group plc - Interim Results for the Six Months Ended 31 December 2021 | Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces its results for the six months ended 31 December 2021 (the "Period") and follows the... |
| 15.03.2022 | Tissue Regenix Group plc - Final year results for the year ended 31 December 2021 | Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces its final results for the year ended 31 December 2021. Financial Highlights Returned to double digit revenue growth up 20% to US$19.7m (2020: US$... |
| 09.03.2022 | Tissue Regenix Group plc - Distribution agreement for OrthoPure® XT | Exclusive distribution agreement for OrthoPure ® XT with Geistlich Biomaterials Italia Tissue Regenix Group (AIM:TRX), the regenerative medical devices company, announces that it has signed an exclusive distribution agreement w... |
| 09.03.2022 | Diurnal Group plc - Interim Results Investor Presentation | Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, today announces that Martin Whitaker, Chief Executive Officer, and Richard Bungay, Chief Financial Office... |
| 07.03.2022 | Microbiotica Ltd - Raises £50m ($67m) to advance pipeline of microbiome-based therapeutics | Funds Phase 1b clinical trials in immuno-oncology and ulcerative colitis and expansion of microbiome-based product pipeline to other indications Series B funding round co-led by new investors Tencent and Flerie Invest, with addit... |
| 02.03.2022 | Tissue Regenix Group plc - Notice of Results | Tissue Regenix (AIM: TRX), the regenerative medical devices company, will announce its final results for the year ended 31 December 2021 on Tuesday 15 March 2022. Investor Briefing Daniel Lee, Chief Executive Officer, and David Cock... |
| 02.03.2022 | Diurnal Group plc - Regulatory update on oral native testosterone | Targeting H2 2022 start for Phase 1 study with DNL-0300 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that it has received feedback from t... |
| 02.03.2022 | Abingdon Health plc - Trading and Strategic Update | Focus on three strategic growth areas: Contract service, e-commerce and own product development AppDx ® smartphone solution achieves critical technical performance milestone ready for commercial launch Abingdon Health plc (AIM... |
| 02.03.2022 | Abingdon Health plc - Data from UK Government led study gives insight into protection from SARS-CoV-2 | UK Government commissioned study working toward setting antibody level thresholds to determine protection levels Building case for antibody testing to support vaccine and workplace COVID-19 strategies AbC-19 TM Semi-Q Rapid Test... |
| 28.02.2022 | Mirriad Advertising plc - Entry into Japanese advertising market | Mirriad and Fuji Television Network Inc. deliver Japanese in-content first Mirriad, the leading in-content advertising company, today announces a new collaboration with Japanese television network, Fuji TV, that launched the Company's ... |
| 24.02.2022 | Diurnal Group plc - Notice of Interim Results | Diurnal Group plc ("Diurnal" or the "Company") Notice of Interim Results Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, w... |
| 23.02.2022 | Mirriad Advertising plc - Independent data from Nielsen demonstrates superior audience reach of in-content advertising compared with traditional TV advertising and First major partnership in Canada | Mirriad, the leading in-content advertising company, is pleased to announce a new partnership in the strategically important North American market and an update on strong campaign metrics illustrating significant audience reach advantages... |
| 16.02.2022 | Itaconix plc - Investor Event | Investor Event Itaconix (AIM: ITX) (OTCQB: ITXXF), a leader in plant-based specialty polymers used as essential ingredients in everyday consumer products, is pleased to announce that the Company will hold a question-and-answer sessio... |
| 14.02.2022 | Bramble Energy Ltd - Secures £35m to fund its game-changing technology | London-based fuel cell company Bramble Energy has closed a £35million investment round to help further expand its game changing capabilities in solving key challenges in the production and implementation of hydrogen fuel cell stacks. Cur... |
| 14.02.2022 | First Light Fusion Ltd - Announces close of Series C fund raise | First Light Fusion, an Oxford-based global leader in researching energy generation via inertial fusion, is pleased to confirm the first close of its Series C fund raise, raising $45 million from both existing and new investors. Existin... |
| 10.02.2022 | Diurnal Group plc - First patient dosed in Phase 2 trial | First patient dosed in Phase 2 clinical trial with modified-release hydrocortisone in adults with adrenal insufficiency Data from CHAMPAIN European study expected in H2 2022 Positive data could lead to regulatory approval in AI ... |
| 09.02.2022 | Itaconix plc - First Trial for Company's Sustainable Superabsorbent | Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based specialty polymers used as essential ingredients in everyday consumer products, is pleased to announce that it has supplied product for the first production trial usin... |
| 26.01.2022 | Itaconix plc - Trading Update for the year ended 31 December 2021 | Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based specialty polymers used as essential ingredients in everyday consumer products, is pleased to update the market on trading for the full year to 31 December 2021. Th... |
| 26.01.2022 | Diffblue Ltd - Diffblue Closes Investment Round to Take Total Venture Funding to $32 Million | Pioneer in using artificial intelligence to automate writing unit tests, Diffblue helps companies ensure the quality of billions of lines of Java software Diffblue, creators of the world’s first AI-for-code solution that automates writ... |
| 26.01.2022 | Diurnal Group plc - Trading update | Strong sales growth (+75%) driven by good Alkindi ® performance and first sales of Efmody ® Initial launches of Efmody ® in Germany, UK and Austria in line with the Company's expectations Diurnal Group plc (AIM: DNL), the speci... |
| 25.01.2022 | Intelligent Ultrasound Group plc - Announcement of additional new product agreement with GE Healthcare | Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial intelligence (AI) software and simulation group, announces that it has signed an extension to its existing exclusive women's healthcare AI agreement with GE Healthcare... |
| 24.01.2022 | Mirriad Advertising plc - Mirriad Advertising plc | Accelerating customer adoption and traction in the key US Market Mirriad, the leading in-content advertising company, today issues a trading update for the year ended 31 December 2021 ("FY2021"). Trading Update Total re... |
| 13.01.2022 | Oxford Nanopore Technologies plc - Fastest human genome sequence uses Oxford Nanopore Scientists describe new approach in NEJM, using Oxford Nanopore DNA sequencing technology to improve prognosis in... | Scientists describe new approach in NEJM, using Oxford Nanopore DNA sequencing technology to improve prognosis in critically ill patients, in less than 8 hours Oxford Nanopore worked with a team led by Stanford University School of Med... |
| 11.01.2022 | Diurnal Group plc - Operational Update | First clinical trial sites initiated in both CONnECT and CHAMPAIN studies for Chronocort ® DITEST™ IND application to be submitted during January 2022 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting pat... |
| 10.01.2022 | Carisma Therapeutics Inc.- Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology | Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration will combine Carisma's engineered macrophage technologywith Moderna's mRNA and LNP techn... |
| 10.01.2022 | Crescendo Biologics Ltd - BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies | Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies aga... |
| 07.01.2022 | Oxford Nanopore Technologies plc - Update to FY21 revenue guidance | ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE UK VERSION OF THE MARKET ABUSE REGULATION (EU NO. 596/2014) WHICH FORMS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. 7 January 2022 Oxfor... |
| 22.12.2021 | Itaconix plc - First Order for New Use in Sustainable Fashion | Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based specialty polymers used as essential ingredients in everyday consumer products, is pleased to announce the first customer order in a new potentially major application ... |
| 20.12.2021 | Abingdon Health plc - Results of General Meeting and Open Offer Issue of Equity and Total voting rights | Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces that all resolutions put to shareholders at the General Meeting held earlier today in connection with... |
| 17.12.2021 | First Light Fusion Ltd - Professor Andrew Randewich joins Scientific Advisory Board | First Light Fusion, a global leader in researching energy generation via inertial fusion, is pleased to announce the appointment of Professor Andrew Randewich to its Scientific Advisory Board. Professor Randewich is Executive Director,... |
| 16.12.2021 | Navenio - UK Scaleup Navenio Secures $12.6M Investment to Accelerate Global Growth in Healthcare and Beyond | UK Scaleup Navenio Secures $12.6M Investment to Accelerate Global Growth in Healthcare and Beyond • Oxford University spin-out’s indoor location-based platform adds to last year’s $11M Series A investment to improve workforce effici... |
| 07.12.2021 | Oxbotica - Oxbotica appoints former Microsoft and Amazon Web Services MD Gavin Jackson as CEO | Oxbotica, global leader in open autonomous vehicle software, has today announced that Gavin Jackson has been appointed new CEO. Gavin joins Oxbotica with unrivalled experience in the technology sector, having previously held senior leade... |
| 07.12.2021 | Applied Graphene Materials plc - AGM Receives UK Patent for Water-based Anti-corrosion Innovation | Industry leader gains formal recognition for its latest nanotechnology development Applied Graphene Materials (LSE:AGM), the producer of specialty graphene nanoplatelet dispersions, is pleased to announce the issuance of UK Patent No. ... |
| 06.12.2021 | CARISMA Therapeutics Inc. - Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study | Carisma Therapeutics. , a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has entered into a clinical study collaboration with Merck (known as MSD outside... |
| 02.12.2021 | Diurnal Group plc - Notice of R&D Day | Diurnal Group plc - Notice of R&D Day Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces it will host an R&D Day for analysts and institu... |
| 02.12.2021 | Oxford Nanopore Technologies plc - Announces technology updates at Nanopore Community Meeting | Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that del... |
| 01.12.2021 | Abingdon Health plc - PrimaryBid Offer | Abingdon Health plc (LON: ABDX ) the AIM quoted international developer and manufacturer of high quality and effective rapid tests, is pleased to announce, a conditional offer for subscription via PrimaryBid (the "PrimaryBidOffer... |
| 01.12.2021 | Abingdon Health plc - Proposed Placing, Subscription, Open Offer and PrimaryBid Offer to raise, in aggregate, no less than £4.0 million | Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces a proposed placing (the "Placing"), via an accelerated bookbuild (the "Bookbuild"... |
| 29.11.2021 | Applied Graphene Materials plc - Applied Graphene Materials to Webcast Live at VirtualInvestorConferences.com December 2nd 2021 | AGM invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation on VirtualInvestorConferences.com Applied Graphene Materials plc (LSE: AGM; OTCQX: APGMF), based in... |
| 23.11.2021 | Ieso Digital Health Ltd - ieso raises $53m to address global mental health crisis with digital therapeutics | UK innovator closes Series B financing to develop AI-enabled, evidence-based digital therapeutics built on the world's largest mental health treatment data set ieso has completed its £39million ($53 million) Series B financing rou... |
| 19.11.2021 | Diurnal Group plc - Results of the Annual General Meeting | Results of Annual General Meeting Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its A... |
| 18.11.2021 | Artios Pharma Ltd - Appoints Nora Brennan to Board of Directors and Audit Committee Chair | Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response process in order to treat patients suffering from a broad range of cancers, anno... |
| 18.11.2021 | Mirriad Advertising plc - Mirriad and CANAL+ Brand Solutions deliver in-content first for French cinema | Mirriad, the leading in-content advertising company, announces a partnership with CANAL+ Brand Solutions to launch a new premium advertising offer. In a first for French cinema, CANAL+ Brand Solutions is now offering advertisers the use ... |
| 17.11.2021 | Mirriad Advertising plc - Mirriad and Crown Media unwrap enhanced Christmas partnership | Mirriad, the leading in-content advertising company, has today announced a new initiative with Crown Media Family Networks, a US-based media production company owned and operated by Hallmark Cards, Inc. The ongoing agreement - which no... |
Show more
Mentions in press and media 285
| Date | Title | Description |
| 21.07.2026 | Mach42 Raises £7M in Pre-Series A Funding | Mach42, an Oxford, UK-based AI-driven company developing technology to accelerate analog circuit simulation for semiconductor design, raised £7M in Pre-Series A funding. The round was led by IP Group plc, with participation from BGF and For... |
| 19.05.2026 | Mantle8 Secures €31M for Global Natural Hydrogen Quest | Mantle8, a pioneering French clean-tech company, has secured €31 million in Series A funding. This substantial capital propels a global exploration and drilling campaign. The mission: to identify the first commercially exploitable, high-pur... |
| 19.05.2026 | Lansdowne Partners Ignites UK Innovation with New $150M VC Fund | Lansdowne Partners launched a pivotal new venture capital fund. It targets high-potential UK innovation. The fund secured $150 million in its initial close. It aims to bridge critical funding gaps. UK companies emerging from university rese... |
| 14.05.2026 | Mantle8: €31 Million Raised For Natural Hydrogen Exploration And Drilling Campaign | Mantle8 has raised €31 million in Series A funding to advance its proprietary technology platform and launch a global exploration and drilling campaign aimed at identifying the first commercially exploitable reservoir of high-purity natural... |
| 14.05.2026 | Lansdowne Partners: $150 Million First Close Announced For UK Innovation-Focused VC Fund | Lansdowne Partners has launched a venture capital fund focused on supporting high-potential UK companies emerging from the country’s university research base and startup ecosystem. The fund announced a first close of $150 million and is tar... |
| 13.05.2026 | Mantle8 Raises €31M in Series A Funding | Mantle8, a Grenoble, France-based developer of natural hydrogen exploration and subsurface modeling technologies, raised €31m in a Series A funding round. The round was led by Sandwater, with participation from Breakthrough Energy Ventures,... |
| 04.05.2026 | Barocal Raises $10M in Seed Funding | Barocal Ltd, a Cambridge, UK-based climate technology company, raised $10M in Seed funding. Backers included World Fund, Breakthrough Energy Discovery, Cambridge Enterprise Ventures and IP Group. The company intends to use the funds to scal... |
| 22.04.2026 | STORM Therapeutics Secures $56 Million, Advances Novel Sarcoma Therapy to Phase 2 | STORM Therapeutics, a clinical-stage biotechnology firm, secured $56 million in Series C financing. This significant capital infusion will drive the advancement of STC-15, its groundbreaking first-in-class METTL3 inhibitor. STC-15 has now e... |
| 20.04.2026 | STORM Therapeutics secures $56 million series C financing and doses first patient in phase 2 Sarcoma Trial of STC‑15 | The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April 2026, Cambridge, UK: STORM Th... |
| 16.04.2026 | STORM Therapeutics Raises $56M in Series C Funding | STORM Therapeutics, a Cambridge, UK-based, clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, raised $56M in Series C funding. Backers included M Ventures, Pfizer Ventures, Taiho Ventur... |
| 18.02.2026 | Mundi Ventures: €750 Million First Close For Kembara Fund | Mundi Ventures has announced a €750 million first close for Kembara, described as Europe’s largest dedicated deep tech growth fund, as it works toward a €1 billion target. The fund is now actively investing in breakthrough deep tech science... |
| 06.02.2026 | Douglas Flint received package from Epstein while at HSBC, files show | The incoming chair of Prudential received a mystery package from Jeffrey Epstein while he was finance director of HSBC, the recent release of Epstein files shows. Douglas Flint, who had a decades-long career at Europe’s largest bank, culmin... |
| 05.02.2026 | Funding Europe’s “second renaissance”: Barcelona’s Kembara hits €750 million first close for €1 billion DeepTech fund | Barcelona-based Kembara, which claims to be Europe’s largest dedicated DeepTech growth fund, today announced a €750M first close toward its €1 billion target. The fund is now actively investing in “breakthrough” DeepTech science and enginee... |
| 14.01.2026 | Prudential names HSBC veteran Douglas Flint as new chair | Prudential has tapped the former chairman of banking juggernaut HSBC Douglas Flint as its new chair. The London-listed financial services giant said on Tuesday Flint would succeed retiring Shriti Vadera, who has been in the post since Janua... |
| 27.11.2025 | Obulytix Strengthens Senior Leadership with Key Executive and Board Appointments | Ghent, Belgium – November 27th, 2025 – Obulytix, the biotechnology company pioneering Precision Lysin Therapeutics (PLTs) — a novel class of targeted biologics designed as next-generation antibiotics — today announces the appointment of Guy... |
| 19.11.2025 | Artios Pharma Secures $115M to Advance Cancer Therapies | Artios Pharma, a UK-based biotech firm, has secured $115 million in Series D funding. The financing aims to boost the development of its precision cancer treatments. Focus on DNA damage response (DDR) is key. Funds will advance clinical tri... |
| 17.11.2025 | Artios raises $115M Series D to accelerate first-in-class cancer therapies | Biotech company Artios today announced the successful close of an oversubscribed $115 million Series D financing. Artios is pioneering next-generation approaches in the DNA damage response (DDR) field through its comprehensive anti-cancer a... |
| 17.11.2025 | €99 million Series D fuels Artios’ expansion of precision cancer treatment pipeline | Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 mi... |
| 15.11.2025 | Rage Biotech: Monash University Spin-Off Raises A$29 Million Series A To Advance RNA Therapeutics Toward Clinical Trials | RAGE Biotech, a Monash University spin-off, has secured A$29 million in Series A financing to accelerate the development of its next-generation RNA-based therapeutics for the treatment of chronic inflammatory diseases. The investment repres... |
| 04.11.2025 | Diffblue’s Latest Innovations in Unit Test Generation Deliver 20x Productivity Advantage Versus AI Coding Assistants | Diffblue today announced the release of the next generation of its flagship product, Diffblue Cover, to address the unmet need for automated, high quality unit test generation at scale. Focused on empowering software development teams to sy... |
| 17.10.2025 | Inside the UK’s innovation surge: record spinout funding, AI initiatives, and academic momentum | Amid record funding and growth, Britain is shaping itself as a top innovation powerhouse – and it’s doing so by reinvesting in an age-old advantage: its universities. This time, however, it’s not just academia leading the charge. A three-pr... |
| 15.10.2025 | UK Spinouts Look to US as Scale-Up Funding Stalls | University spinouts are facing a funding bottleneck, with only a handful of emerging companies across critical sectors like AI, quantum, and biotech raising enough to scale, according to the latest figures from Beauhurst. The analytics firm... |
| 15.10.2025 | Mission Therapeutics Raises $13.3M in Funding | Mission Therapeutics, a Cambridge, UK-based clinical-stage biotech developing first-in-class therapeutics that promote cell and organ health by enhancing mitophagy, raised $13.3m in funding. The financing was led by current investors Pfizer... |
| 03.10.2025 | OXCCU Secures $28M to Transform Aviation with Low-Cost Sustainable Fuel | OXCCU, an Oxford University spin-out, secured $28 million in Series B funding. This propels its single-step carbon-to-SAF technology. The innovative process converts waste carbon directly into sustainable aviation fuel, drastically cutting ... |
| 01.10.2025 | OXCCU: Oxford University Spin-Out Secures $28 Million Series B | OXCCU, a spin-out from the University of Oxford specializing in innovative carbon recycling technologies, has announced the successful completion of a £20.75 million ($28 million) Series B funding round, which was oversubscribed. This fundi... |
| 29.09.2025 | Oxford University spin-out OXCCU raises €23.7 million to scale waste-carbon-to-fuel process | OXCCU, an Oxford University spin-out developing a one-step process to convert waste carbon into SAF, has raised €23.7 million in an oversubscribed Series B funding round to accelerate its commercialisation efforts, expand its operations, an... |
| 29.09.2025 | OXCCU Raises $28m in Series B Funding to Scale Sustainable Aviation Fuel from Waste Carbon | Backed by global leaders in aviation, energy, and climate investing, OXCCU strengthens its position as a critical player in the global push for commercially viable sustainable aviation fuel (SAF). Series B investors include IAGi Ventures (t... |
| 20.06.2025 | Northern Gritstone and Parkwalk: A New Dawn for UK Innovation | In the heart of the UK, a new venture is stirring the pot of innovation. Northern Gritstone, a Manchester-based investment firm, has joined forces with Parkwalk Advisors from London. Together, they are launching the Northern Universities Ve... |
| 19.06.2025 | Northern Gritstone and Parkwalk team up for new EIS fund – will it deliver the UK’s first trillion-euro startup? | Manchester-based investment company Northern Gritstone has partnered with London-based Parkwalk Advisors to launch the Northern Universities Venture Fund, an Enterprise Investment Scheme (EIS) fund designed to offer investors early-stage ac... |
| 03.06.2025 | AccelerComm: Pioneering the Future of 5G with Satellite Technology | In a world where connectivity is king, AccelerComm is making waves. The Southampton-based startup has just secured €13.1 million in funding, a significant boost for its mission to deliver universal mobile coverage through satellite-based 5G... |
| 02.06.2025 | British startup AccelerComm secures €13.1 million to help deliver universal mobile coverage | Southampton-based AccelerComm, a company delivering 5G technology for Satellite networks, today announced that it has closed a funding round totalling €13.1 million to accelerate deployments of their 5G satellite communications products and... |
| 02.06.2025 | AccelerComm raises $15M to advance satellite-based 5G | UK-based wireless technology company AccelerComm has secured $15 million in funding to expand its work on 5G solutions for satellite networks, aiming to accelerate the delivery of universal mobile coverage via space-based infrastructure. Th... |
| 22.03.2025 | Brainomix: £14 Million (Series C) Closed For Advancing AI Imaging In Healthcare | Brainomix, a company pioneering AI-based imaging tools in stroke and lung fibrosis, announced the completion of a £14 million ($18 million) Series C investment round. The funding round was co-led by prominent healthtech investors that inclu... |
| 21.03.2025 | Brainomix Secures £14M to Revolutionize Stroke and Lung Fibrosis Treatment | In the fast-paced world of healthcare technology, Brainomix is making waves. The Oxford-based company has just raised £14 million in Series C funding. This investment is a lifeline, aimed at expanding its reach into the U.S. market. With a ... |
| 20.03.2025 | Brainomix Raises £14M in Series C Funding | Brainomix, an Oxford, UK-based company providing AI-powered imaging tools in stroke and lung fibrosis, raised £14M in Series C funding. The round was led by co-led by Parkwalk Advisors, and the Boehringer Ingelheim Venture Fund (BIVF), alon... |
| 15.12.2024 | Pharming announces a recommended cash offer of SEK 0.45 per share to the shareholders of Abliva | Pharming announces a recommended cash offer of SEK 0.45 per share to the shareholders of Abliva Sun, Dec 15, 2024 19:45 CET Report this content This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Ko... |
| 06.11.2024 | Diffblue: AI-For-Code Software Company Raises $6.3 Million | Diffblue, a creator of the world’s first fully autonomous generative AI-for-code software, announced it raised $6.3 million in new capital as it reached a record six-month period with 326% net new ARR growth from the previous six months. To... |
| 30.10.2024 | Oxford-based Diffblue secures €5.8 million to fuel momentum for generative AI-for-code | Diffblue, creators of the world’s first fully autonomous generative AI-for-code software, announced it has secured €5.8 million in new capital as it reaches a record six-month period with 326% net new ARR growth from the prior six months. T... |
| 30.10.2024 | Diffblue Raises $6.3M in Funding | Diffblue, an Oxford, UK-based creator of autonomous generative AI-for-code software, raised $6.3M in funding. The round was led by IP Group, Parkwalk Advisors, and AlbionVC, with additional participation from Oxford University, and private ... |
| 30.10.2024 | Diffblue raises $6.3M for autonomous AI-powered test generation platform Your vote of support is important to us and it helps us keep the content FREE. One click below supports our mission to provide ... | Diffblue Ltd., the maker of an autonomous generative artificial intelligence code test platform, said today it secured $6.3 million in new funding to build on its differentiated approach to generating unit tests for Java. The new capital ca... |
| 26.09.2024 | Visa to Acquire Featurespace | Visa (NYSE: V) announced it has signed a definitive agreement to acquire Featurespace, a Cambridge, UK-based developer of real-time artificial intelligence (AI) payments protection technology. The amount of the deal was not disclosed. The t... |
| 11.09.2023 | Why AgFunder invested in Azaneo’s low-power electric weeding tech | Editor’s Note: Azaneo recently announced a AUD $1.4 million ($893,000) pre-seed round led by Tenacious Ventures with participation from AgFunder and IP Group. Here, we dive into why AgFunder chose to back the Australian startup’s rapid-puls... |
| 11.05.2023 | AccelerComm’s signal gets supercharged with £21.5 million funding round | Southhampton-based IP company AccelerComm provides solutions which enable optimal performance of 5G radio access networks. It is used to correct mobile transmission errors caused by noise, interference and poor signal strength - popular amo... |
| 16.02.2023 | Oxford University spinout Lumai secures £1.1m Innovate UK Smart Grant to power optical computing revolution | - Oxford start-up to bring optical neural networks to the UK market, which can be 1000x faster than traditional approaches London, UK, 16th February 2023: Lumai, the start-up unlocking the potential of optical computing, today announced tha... |
| 19.07.2022 | Parkwalk – The UK’s leading university spinout investor, CEO features in UKTN | As the UK’s leading investor in university spinouts, Parkwalk’s CEO, Moray Wright, discusses the origins of Parkwalk, the challenges of early-stage funding, and some of the largest Parkwalk investments to date, in UKTN‘s article. |
| 13.07.2022 | Parkwalk Advisors: Meet the UK’s most active investor in academic spinouts | The UK has a thriving spinout ecosystem. Innovative technologies cultivated in academia have gone on to raise millions in capital and exit in blockbuster IPOs. But who is the most active investor in UK university spinouts? According to a re... |
| 26.05.2022 | EXCLUSIVE: Moa nets $44m Series B funding to launch the next generation of herbicides | UK-based ag biotech startup Moa Technology has raised £35 million ($44 million) for its latest funding round, AFN can exclusively reveal. It’s aiming to tackle the growing problem of herbicide resistance by taking a new approach to the disc... |
| 03.05.2022 | London-based SLAMcore raises $16 million to enable robots read the room | London-headquartered vision-based location and mapping platform for robots, SLAMcore has raised $16 million in funding. The Series A round was led by ROBO Global Ventures and Presidio Ventures who invested alongside Amadeus Capital, Global ... |
| 11.04.2022 | London’s GripAble gets $11 million to increase its grip on the US market | With many patients being isolated at home and unable to attend therapy appointments owing to the Covid-19 situation, home monitoring health care startups have been getting a lot of attention. While last week, Grenoble-based company CardioRe... |
| 07.03.2022 | Tencent backs Cambridge-based startup in $67 million funding to address opportunities in biomedicine | Cambridge-based player in the field of microbiome-based therapeutics, biomarkers and targets, Microbiotica has raised £50 million ($67 million) funding. The Series B round was co-led by Flerie Invest and Tencent with participation from new ... |
| 18.02.2022 | BGF-backed Bramble Energy secures £35m to support net zero mission | London-based fuel cell company Bramble Energy has closed a £35 million investment round to help further expand its game changing capabilities in solving key challenges in the production and implementation of hydrogen fuel cell stacks. This... |
| 15.02.2022 | Zero-carbon refrigeration pioneer Barocal secures £1.3m funding to explore heating systems | Zero-carbon refrigeration pioneer Barocal secures a £1.3 million investment to accelerate commercialisation of its novel technology designed to dramatically cut global CO₂ emissions. As the technology also works in heating applications, the... |
| 14.02.2022 | IP : First Light Fusion Ltd - Announces close of Series C fund raise | First Light Fusion, an Oxford-based global leader in researching energy generation via inertial fusion, is pleased to confirm the first close of its Series C fund raise, raising $45 million from both existing and new investors. Existing inv... |
| 10.02.2022 | IP : Diurnal Group plc - First patient dosed in Phase 2 trial | First patient dosed in Phase 2 clinical trial with modified-release hydrocortisone in adults with adrenal insufficiency Data from CHAMPAIN European study expected in H2 2022 Positive data could lead to regulatory approval in AI in 2023 Addr... |
| 26.01.2022 | IP : Diffblue Ltd - Diffblue Closes Investment Round to Take Total Venture Funding to $32 Million | Pioneer in using artificial intelligence to automate writing unit tests, Diffblue helps companies ensure the quality of billions of lines of Java software Diffblue, creators of the world's first AI-for-code solution that automates writing J... |
| 26.01.2022 | IP : Diurnal Group plc - Trading update | Strong sales growth (+75%) driven by good Alkindi® performance and first sales of Efmody® Initial launches of Efmody® in Germany, UK and Austria in line with the Company's expectations Diurnal Group plc (AIM: DNL), the specialty pharmaceuti... |
| 25.01.2022 | IP : Intelligent Ultrasound Group plc - Announcement of additional new product agreement with GE Healthcare | Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial intelligence (AI) software and simulation group, announces that it has signed an extension to its existing exclusive women's healthcare AI agreement with GE Healthcare t... |
| 16.12.2021 | IP : Navenio - UK Scaleup Navenio Secures $12.6M Investment to Accelerate Global Growth in Healthcare and Beyond | UK Scaleup Navenio Secures $12.6M Investment to Accelerate Global Growth in Healthcare and Beyond • Oxford University spin-out's indoor location-based platform adds to last year's $11M Series A investment to improve workforce efficiency in ... |
| 16.12.2021 | UK Scaleup Navenio Secures $12.6M Investment to Accelerate Global Growth in Healthcare and Beyond | Oxford University spin-out’s indoor location-based platform adds to last year’s $11M Series A investment to improve workforce efficiency in healthcare and other verticals The Oxford Science Enterprises-led round will support expansion in th... |
| 07.12.2021 | IP : Oxbotica - Oxbotica appoints former Microsoft and Amazon Web Services MD Gavin Jackson as CEO | Oxbotica, global leader in open autonomous vehicle software, has today announced that Gavin Jackson has been appointed new CEO. Gavin joins Oxbotica with unrivalled experience in the technology sector, having previously held senior leadersh... |
| 07.12.2021 | IP : Applied Graphene Materials plc - AGM Receives UK Patent for Water-based Anti-corrosion Innovation | Industry leader gains formal recognition for its latest nanotechnology development Applied Graphene Materials (LSE:AGM), the producer of specialty graphene nanoplatelet dispersions, is pleased to announce the issuance of UK Patent No. GB258... |
| 07.12.2021 | IP : CARISMA Therapeutics Inc. - Announces Collaboration with Merck to Evaluate CAR-Macrophages in Combination with KEYTRUDA® (pembrolizumab) in a Clinical Study | Carisma Therapeutics., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has entered into a clinical study collaboration with Merck (known as MSD outside the... |
| 02.12.2021 | IP : Oxford Nanopore Technologies plc - Announces technology updates at Nanopore Community Meeting | Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that deliv... |
| 02.12.2021 | IP : Diurnal Group plc - Notice of R&D Day | Diurnal Group plc - Notice of R&D Day Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces it will host an R&D Day for analysts and institutio... |
| 01.12.2021 | IP : Abingdon Health plc - PrimaryBid Offer | Abingdon Health plc (LON: ABDX) the AIM quoted international developer and manufacturer of high quality and effective rapid tests, is pleased to announce, a conditional offer for subscription via PrimaryBid (the "PrimaryBidOffer")... |
| 01.12.2021 | IP : Abingdon Health plc - Proposed Placing, Subscription, Open Offer and PrimaryBid Offer to raise, in aggregate, no less than £4.0 million | Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces a proposed placing (the "Placing"), via an accelerated bookbuild (the "Bookbuild" o... |
| 29.11.2021 | IP : Applied Graphene Materials plc - Applied Graphene Materials to Webcast Live at VirtualInvestorConferences.com December 2nd 2021 | AGM invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation on VirtualInvestorConferences.com Applied Graphene Materials plc (LSE: AGM; OTCQX: APGMF), based in Redc... |
| 23.11.2021 | IP : Ieso Digital Health Ltd - ieso raises $53m to address global mental health crisis with digital therapeutics | UK innovator closes Series B financing to develop AI-enabled, evidence-based digital therapeutics built on the world's largest mental health treatment data set ieso has completed its £39million ($53 million) Series B financing round led by... |
| 19.11.2021 | IP : Diurnal Group plc - Results of the Annual General Meeting | Results of Annual General Meeting Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that all resolutions proposed to shareholders at its Annual Gen... |
| 18.11.2021 | IP : Mirriad Advertising plc - Mirriad and CANAL+ Brand Solutions deliver in-content first for French cinema | Mirriad, the leading in-content advertising company, announces a partnership with CANAL+ Brand Solutions to launch a new premium advertising offer. In a first for French cinema, CANAL+ Brand Solutions is now offering advertisers the use of ... |
| 18.11.2021 | IP : Artios Pharma Ltd - Appoints Nora Brennan to Board of Directors and Audit Committee Chair | Artios Pharma Limited (Artios), a leading biotech company pioneering the development of novel small molecule therapeutics that target the DNA damage response process in order to treat patients suffering from a broad range of cancers, announ... |
| 17.11.2021 | IP : Mirriad Advertising plc - Mirriad and Crown Media unwrap enhanced Christmas partnership | Mirriad, the leading in-content advertising company, has today announced a new initiative with Crown Media Family Networks, a US-based media production company owned and operated by Hallmark Cards, Inc. The ongoing agreement - which now inc... |
| 17.11.2021 | IP : Ultraleap Holdings Ltd - Raises £60 million in Series D fundraise to be the primary interface for the metaverse | Round will scale the group's technologies and accelerate the shift to the next-gen computing platform for their verticals Ultraleap, the world leader in interface technologies - hand trackingand mid-air haptics - today announced it has comp... |
| 16.11.2021 | IP : Diurnal Group plc - Alkindi® approved by Swissmedic for use in Switzerland | Market launch by EffRx Pharmaceuticals expected during H1 2022 to address unmet need in paediatric AI Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, annou... |
| 15.11.2021 | IP : Diurnal Group plc - Directorate Changes | Appointment of Chairman and two Non-Executive Directors with extensive industry experience to support commercial growth Anders Härfstrand, Deborah Jorn, and Jean-Michel Cosséry will join the Board with immediate effect Diurnal Group plc (AI... |
| 29.10.2021 | Hinge Health - Hinge Health reaches $6.2 billion valuation and has more than doubled its customer base YoY to over 575 enterprise customers | SAN FRANCISCO- Oct. 28, 2021 - Hinge Health, the world's #1 Digital Musculoskeletal Clinic™, today announced $400 million Series E financing to meet the growing demand from millions of Americans seeking accessible care for back and joint pa... |
| 28.10.2021 | MOBILion Systems - Pennsylvania science start-up MOBILion Systems extends successful launch of new technology | Pennsylvania science start-up MOBILion Systems extends successful launch of new technology Chadds Fords, PA, October 28, 2021: MOBILion Systems Inc. is celebrating the culmination of a successful year as it showcases its first commercial Hi... |
| 20.10.2021 | IP : Crescendo Biologics Ltd - Crescendo Biologics announces prestigious new collaboration with The Institute of Cancer Research, London | Crescendo Biologics Ltd (Crescendo), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announces a new translational science collaboration with The Institute of Cancer Research, London,... |
| 15.10.2021 | IP : Oxford Nanopore Technologies plc - Upgrade to full-year revenue guidance | Oxford Nanopore Technologies plc Trading update Upgrade to full-year revenue guidance Oxford Nanopore Technologies plc (the "Group"), the company behind a new generation of nanopore-based sensing technology, today provides an upda... |
| 14.10.2021 | IP : Diurnal Group plc - Agreement signed with ExCEEd Orphan for CEE | Diurnal Group plc Distribution agreement signed with ExCEEd Orphan for Central and Eastern Europe Agreement extends the Company's commercial footprint to over two-thirds of the European Economic Area population Diurnal Group plc (AIM: DNL),... |
| 13.10.2021 | IP : Applied Graphene Materials plc - Full year results for the year ended 31 July 2021 | Applied Graphene Materials (LSE:AGM), the producer of specialty graphene materials and dispersions, announces its full year results for the year ended 31 July 2021. Operational and commercial highlights: 40 products available to distributor... |
| 11.10.2021 | IP : Diurnal Group plc - Phase 1 data for DITEST published in EJE | US IND submission for the Company's third novel product expected in Q4 2021 Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the results from... |
| 07.10.2021 | IP : First Light Fusion - Represents UK fusion sector at the UK Government's Global Investment Summit | 7 October 2021 Oxford, UK: First Light Fusion, a global leader in researching energy generation via inertial fusion, is pleased to announce that it has been selected to appear as one of the twelve showcase companies at the UK Department for... |
| 07.10.2021 | IP : Applied Graphene plc - Investor Presentation | Investor Presentation Applied Graphene Materials (LSE:AGM), the producer of specialty graphene materials, is pleased to announce that its CEO Adrian Potts and CFO David Blain will provide a live presentation on the Company's Preliminary Res... |
| 06.10.2021 | IP : Mirriad Advertising plc - In-content first for UK's favourite property show | Mirriad delivers in-content first for UK's favourite property show Mirriad, the leading in-content advertising company, today announces its collaboration with Electric Glue and 4Sales to incorporate a novel in-content product placement for ... |
| 05.10.2021 | IP : Applied Graphene Materials plc - AGM joins the GEIC | AGM joins the Graphene Engineering and Innovation Centre in collaboration with The Graphene Council Applied Graphene Materials (LSE:AGM), the producer of specialty graphene nanoplatelet dispersions, announces that it has joined the Graphene... |
| 30.09.2021 | IP : Mirriad Advertising plc - Mirriad launches new CPM pricing model via partnership with Tencent in China | Mirriad, the leading in-content advertising company, today announces the launch of a new cost-per-thousand (CPM) pricing model delivered in partnership with Tencent in China. This important next step in the Company's renewed partnership wit... |
| 28.09.2021 | IP : Itaconix plc - Half year results for the period ended 30 June 2021 | Itaconix (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based specialty polymers used as essential ingredients in everyday consumer products, is pleased to announce its unaudited interim results for the six months ended 30 June 202... |
| 23.09.2021 | IP : Itaconix plc - Notice of Interim Results and Investor Presentation | Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in plant-based specialty polymers, announces that its Interim Results for the period ended 30 June 2021 will be released on 28 September 2021. Investor Presentation A live online p... |
| 23.09.2021 | IP : Xeros Technology Group plc - 2021 Interim Results | Xeros Technology Group plc (AIM: XSG, 'the Group', 'Xeros'), the licensor of proprietary solutions improving the sustainability and economics of garments and fabrics, today publishes its interim results for the six months ended 30 June 2021... |
| 20.09.2021 | IP : Mirriad Advertising plc - Mirriad signs partnership agreement with Influential | Mirriad, the leading in-content advertising company, today announces a strategic partnership with Influential, the world's largest influencer marketing company. Representing a significant opportunity, the agreement will expand the range of ... |
| 20.09.2021 | IP : Applied Graphene Materials plc - Four further products launched by AGM customers | Applied Graphene Materials (LSE:AGM), the producer of specialty graphene nanoplatelet dispersions, is delighted to announce that its ongoing customer engagements have led to the launch to market of four further customer products enhanced wi... |
| 15.09.2021 | IP : Actual Experience plc - Board Changes | Actual Experience (AIM: ACT), the analytics-as-a-service company, announces the following changes to its board structure, further to the RNS dated 8 April 2021. As per the previous announcement, Stephen Davidson will be retiring from his ro... |
| 15.09.2021 | IP : Intelligent Ultrasound Group plc - Directorate Change | Appointment of Michele Lesieur to Board Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial intelligence (AI) software and simulation company, announces that Michele Lesieur will be joining the Board as a Non-executive Di... |
| 14.09.2021 | IP : Diurnal Group plc - Results for the year ended 30 June 2021 | Significant progress made during the year with two major regulatory approvals Alkindi® growth of 18% in core markets despite continued impact of Covid-19 on hospital visits Post-period, launch of Efmody® in Europe, Diurnal's second product ... |
| 13.09.2021 | IP : Diurnal Group plc - Commercial launch of Efmody® in the UK | Follows recent European launch in Germany and Austria Provides a new treatment option for adult and adolescent patients suffering from CAH in the UK Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs ... |
| 09.09.2021 | IP : Centessa Pharmaceuticals plc - Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis | 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated ~ ~ Company has initiated planning for glob... |
| 08.09.2021 | IP : Tissue Regenix Group plc - Half-year Report Interim results for the six months to 30 June 2021 | Tissue Regenix Group (AIM:TRX) ('Tissue Regenix' or the 'Group'), the regenerative medical devices company, announces its unaudited interim results for the six months to 30 June 2021. Financial highlights Group revenues increased by 12% to ... |
| 07.09.2021 | IP : Abingdon Health plc - Launch of Semi-Quantitative Accessory to AbC-19™ | To help indicate the strength of antibody response and possible immunity Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch, initially for rese... |
| 01.09.2021 | IP : Tissue Regenix Group plc - Notice of results | Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that its interim results for the six months ended 30 June 2021 will be announced on Wednesday, 8 September 2021. Investor presentation Daniel Lee, Chief Executiv... |
Show more